Ask AI

Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression

Gain in-depth knowledge on how to integrate novel and emerging agents to manage patients with HR-positive/HER2-negative MBC harboring ESR1 or PIK3CA/AKT1/PTEN alterations following disease progression on endocrine therapy. View an on-demand webcast of a live webinar, download the associated slideset for use in your clinic, and review the expert-authored answers to frequently asked questions.

Share

Program Content

Activities

Biomarker Testing in HRpos HER2neg ABC
Unmet Needs, Mechanisms of Resistance, and Biomarker Testing in HR+/HER2- Advanced Breast Cancer Progressing on First-line CDK4/6 Inhibitor Plus Endocrine Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

SERDs for Advanced Breast Cancer
Clinical Evidence for Next-Generation Approaches Targeting the Estrogen Receptor
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

Targeting PIK3CA AKT PTEN Alterations in ABC
Targeting PIK3CA/AKT/PTEN Alterations: Key Clinical Trials
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2025

Expires: November 29, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Lilly and Stemline Therapeutics, Inc.

AstraZeneca

Lilly

Stemline Therapeutics, Inc.